John R. Mackey, MD

Articles

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

Jean-marc A. Nabholtz, MD;Michael Smylie, MD;John R. Mackey, MD;Dick Au, MD;Evelyn Sansregret, MD;Daniel Noel, MD;Alexander H. Paterson, MD;Taher Al-tweigeri, MD;Fernad Delorme, MD;Allesandro Riva, MD

August 1st 1997

Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastic Breast Cancer

Jean-marc A. Nabholtz, MD;John R. Mackey, MD;Alexander Paterson, MD;Daniel Noel, MD;Taher Al-tweigeri, MD;Anna Janowska, MD;Fe Delorme, MD;Alexander Riva, MD

June 1st 1997

A pilot phase II study examined the feasibility of 75 mg/m² of docetaxel (Taxotere) in combination with 50 mg/m²of doxorubicin and 500 mg/m² of cyclophosphamide (Cytoxan, Neosar) in the first-line treatment of metastatic breast cancer. This study was designed to evaluate the efficacy and toxicity of the docetaxel/doxorubicin/cyclophosphamide combination both alone and as induction before high-dose chemotherapy, supplemented by autologous peripheral blood stem-cell transplantation.